131I‐Meta‐iodobenzylguanidine in the Management of Metastatic Midgut Carcinoid Tumors
- 28 October 2004
- journal article
- case report
- Published by Wiley in World Journal of Surgery
- Vol. 28 (11) , 1157-1162
Abstract
The management of metastatic neuroendocrine tumors incorporates multimodal therapy with surgery, biotherapy, and chemotherapy. Tumor-targeted therapies using radiolabeled octreotide and meta-iodobenzylguanidine (mIBG) represent a novel treatment approach. The aim of this study was to evaluate the effectiveness of 131I-mIBG in the treatment of metastatic midgut carcinoid tumors. survival outcomes were assessed for patients treated at two regional cancer centers and then compared. One center used 131I-mIBG routinely in the management of metastatic carcinoid tumors (center A), and the other did not use this modality (center B). Only patients with histologically proven metastatic carcinoid tumor shown, or thought most likely, to be of midgut origin were included in the study. During the period 1980 to 2002, a series of 58 patients from center A with metastatic carcinoid tumor arising from the midgut underwent multimodality therapy with the addition of 131I-mIBG. Their median age was 64 years. The median dose of 131I-mIBG administered was 6751 MBq, and there was an average of 2.8 treatments per patient. During the same period, 58 patients with metastatic carcinoid were treated at center B with similar multimodality therapy without the use of 131I-mIBG therapy. Their median age was 65 years. Survivals at 3 and 5 years were 77% and 63%, respectively (95% CI 47–75), for group A. The 3- and 5-year survivals for group B were 56% and 47% (95% CI 34–59), respectively. The mean follow-up was 6.6 years for group A and 5.0 years for group B. Although retrospective in nature, this study suggests that the addition of 131I-mIBG therapy to the treatment protocol of patients with metastatic midgut carcinoid tumors prolongs survival.Keywords
This publication has 30 references indexed in Scilit:
- A 5‐decade analysis of 13,715 carcinoid tumorsCancer, 2003
- CORRESPONDENCEEuropean Journal of Surgical Oncology, 2002
- Regression of metastatic carcinoid tumors with octreotide therapy: Two case reports and a review of the literatureJournal of Surgical Oncology, 2002
- 131I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndromeEuropean Journal of Surgical Oncology, 2001
- Long-term palliation in metastatic carcinoid tumours with various applications of meta-iodobenzylguanidin (MIBG)European Journal of Gastroenterology & Hepatology, 1999
- Treatment of malignant phaeochromocytoma, paraganglioma and carcinoid tumours with 131I-metaiodobenzylguanidineNuclear Medicine Communications, 1993
- Octreotide and interferon alfa: A new combination for the treatment of malignant carcinoid tumoursEuropean Journal of Cancer, 1992
- Extended Experience with Recombinant a-2b Interferon with OR Without Hepatic Artery Embolization in the Treatment OF Midgut Carcinoid Tumours A preliminary reportActa Oncologica, 1991
- Carcinoid Tumors of the Gastrointestinal TractSouthern Medical Journal, 1989
- Diagnosis and Treatment of a Carcinoid Tumor Using lodine-131 Meta-iodobenzylguanidineClinical Nuclear Medicine, 1986